Biomarkerforschung in der Neuropsychiatrie: Herausforderung und Potenzial

Zusammenfassung

Der Etablierung von serumbasierten Biomarkern für psychiatrische Erkrankungen stellen sich zahlreiche Hindernisse entgegen. Das Ziel dieser Forschungsvorhaben ist die Verbesserung der Subjektivität im Diagnosealltag der Psychiatrie. Versuche, die molekulare Analyse von Patientenproben einzuführen, trafen bisher jedoch auf beachtlichen Widerstand. Ursächlich für diese zögernde Akzeptanz ist Skepsis im Bezug auf einen Paradigmenwechsel, dass auch periphere Marker Hinweise auf pathologische Zustände des Gehirns und damit der höheren kognitiven Funktionen geben können. Um diesem Trend entgegenzuwirken, haben verschiedene Regulationsorgane des Gesundheitswesens dazu aufgerufen, Forschung und Entwicklung durch biomarkerorientierte Verfahrensweisen zu reformieren, mit dem erklärten Ziel, die Sicherheit und Effizienz von zukünftigen Psychopharmaka zu erhöhen. Um das Potenzial des Biomarkersektors in diesem Zusammenhang hervorzuheben, wird die Einführung von VeriPsych^TM, dem ersten unterstützenden Bluttest in der Diagnose der Schizophrenie, dargelegt.

Abstract

The introduction of blood-based biomarkers for psychiatric disorders faces numerous challenges. The goal of research efforts is the improvement of the current more or less subjective diagnosis, treatment and patient management. So far attempts to introduce molecular analyses have faced considerable resistance. There is an urgent need for a paradigm shift so that peripheral markers may also deliver insights into pathological states of the brain. Health regulators have called for a reform of research and development approaches, with the goal to enhance the safety and efficiency of future antipsychotic drugs using biomarker-based methods. Here we discuss the potential of the biomarker sector in this context, as exemplified by the recent introduction of Veripsych^TM, the first blood test aiding the diagnosis of schizophrenia.

Schlüsselwörter

Biomarker - Schizophrenie - Bluttest - Proteomik - Serum - Diagnostik

Key words

biomarkers - schizophrenia - blood test - proteomics - serum - diagnostics

• Literatur

• 1 Marson B. “Critical Path” is on the road forward; FDA reports industry activity is high. Pink Sheet 2007; 69: 29
• 2 Owens J. Funding for accelerating drug development initiative critical. Nat Rev Drug Discov 2006; 5: 271
• 3 Schwarz E, Izmailov R, Spain M et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010; 5: 39-47
• 4 Noll R. The blood of the insane. Hist Psychiatry 2006; 17: 395-418
• 5 Noll R. American madness: the rise and fall of dementia praecox. Cambridge: Harvard University Press; 2011
• 6 Purcell SM, Wray NR, Stone JL et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752
• 7 Shi J, Levinson DF, Duan J et al. Common variants on chromosome 6p22. 1 are associated with schizophrenia. Nature 2009; 460: 753-757
• 8 Stefansson H, Ophoff RA, Steinberg S et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747
• 9 Mcgue M. When Assessing Twin Concordance, Use the Probandwise Not the Pairwise Rate. Schizophrenia Bull 1992; 18: 171-176
• 10 Tsuang M. Schizophrenia: Genes and environment. Biol Psychiat 2000; 47: 210-220
• 11 Schlotz W, Phillips DIW. Fetal origins of mental health: Evidence and mechanisms. Brain Behav Immun 2009; 23: 905-916
• 12 Jones SR, Fernyhough C. A new look at the neural diathesis – Stress model of schizophrenia: The primacy of social-evaluative and uncontrollable situations. Schizophrenia Bull 2007; 33: 1171-1177
• 13 Spelman LM, Walsh PI, Sharifi N et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007; 24: 481-485
• 14 Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289
• 15 van Nimwegen LJ, Storosum JG, Blumer RM et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008; 93: 572-577
• 16 Szulc A, Galinska B, Konarzewska B et al. Immunological marker activity in first episode schizophrenic patients. Pol Merkur Lekarski 2001; 10: 450-452
• 17 van Venrooij JA, Fluitman SB, Lijmer JG et al. Impaired Neuroendocrine and Immune Response to Acute Stress in Medication-Naive Patients With a First Episode of Psychosis. Schizophr Bull 2010 38: 272-279
• 18 Schwarz E, Guest P, Rahmoune H et al. Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. World Journal of Biological Psychiatry 2011; 13: 627-632
• 19 Agius M, Shah S, Ramkisson R et al. Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team – final results. Psychiatr Danub 2007; 19: 130-138
• 20 Salokangas RK, McGlashan TH. Early detection and intervention of psychosis. A review. . Nord J Psychiatry 2008; 62: 92-105
• 21 Yap HL. Early psychosis intervention. Singapore Med J 2010; 51: 689-693
• 22 Gonzalez-Pinto A, Gutierrez M, Mosquera F et al. First episode in bipolar disorder: misdiagnosis and psychotic symptoms. J Affect Disord 1998; 50: 41-44
• 23 Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry 2001; 62 (Suppl. 14) 5-9
• 24 Thomas P. The many forms of bipolar disorder: a modern look at an old illness. J Affect Disord 2004; 79 (Suppl. 01) S3-S8
• 25 Post RM. The impact of bipolar depression. J Clin Psychiatry 2005; 66 (Suppl. 05) 5-10
• 26 Laughren TP. What's next after 50 years of psychiatric drug development: an FDA perspective. J Clin Psychiatry 2010; 71: 1196-1204
• 27 Goodsaid F, Frueh FW. Implementing the U. S. FDA guidance on pharmacogenomic data submissions. Environ Mol Mutagen 2007; 48: 354-358
• 28 Domenici E, Wille DR, Tozzi F et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: e9166
• 29 Schwarz E, Guest PC, Rahmoune H et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2011; 17: 494-502
• 30 Ellington AA, Kullo IJ, Bailey KR et al. Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 2010; 56: 186-193
• 31 Kashshai D, Mate B. The effect of nicotinic acid on the temperature of the skin of patients with schizophrenia in different states. Zh Nevropatol Psikhiatr Im S S Korsakova 1961; 61: 1688-1698
• 32 Vaddadi KS. Niacin flushing and schizophrenia. Med Hypotheses 1981; 7: 599-600
• 33 Wilson DW, Douglass AB. Niacin skin flush is not diagnostic of schizophrenia. Biol Psychiatry 1986; 21: 974-977
• 34 Smesny S, Klemm S, Stockebrand M et al. Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 79-85
• 35 Fleeman N, Dundar Y, Dickson R et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 2011; 11: 1-14
• 36 Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500
• 37 Guest PC, Wang L, Harris LW et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010; 15: 118-119
• 38 Guest PC, Schwarz E, Krishnamurthy D et al. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011; 36: 1092-1096
• 39 Steiner J, Jacobs R, Panteli B et al. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci 2010; 260: 509-518
• 40 Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale 2000; 26: 12-14
• 41 Dunayevich E, Keck PE Jr. Prevalence and description of psychotic features in bipolar mania. Curr Psychiatry Rep 2000; 2: 286-290
• 42 Ferrier IN, Stanton BR, Kelly TP et al. Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 1999; 175: 246-251
• 43 Bromet EJ, Kotov R, Fochtmann LJ et al. Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 2011; 168: 1186-1194
• 44 Muller N, Riedel M, Schwarz MJ et al. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 255: 149-151
• 45 Baptista T, Rangel N, Fernandez V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93: 99-108
• 46 Henderson DC, Fan X, Sharma B et al. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 2009; 119: 457-465
• 47 Harris LW, Wayland M, Lan M et al. The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 2008; 3: e3964
• 48 Prabakaran S, Swatton JE, Ryan MM et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-697
• 49 Steiner J, Walter M, Wunderlich MT et al. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009; 65: 1107-1110
• 50 Statistisches Bundesamt. Krankheitskostenrechnung. http://www.gbe-bund.de/gbe10 / pkg_isgbe5.prc_isgbe.2010
• 51 Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 1969; 30: 341-344
• 52 Tsuang MT, Perkins K, Simpson JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry 1983; 44: 42-46
• 53 Lancaster-Smith MJ, Strickland I. Coeliac disease and schizophrenia. Lancet 1970; 2: 1090-1091
• 54 Dohan FC. Coeliac disease and schizophrenia. Lancet 1970; 1: 897-898
• 55 Poste G. Bring on the biomarkers. Nature 2011; 469: 156-157